Important considerations for treatment with dietary supplement versus prescription niacin products - PubMed (original) (raw)
Review
Important considerations for treatment with dietary supplement versus prescription niacin products
James M Backes et al. Postgrad Med. 2011 Mar.
Abstract
Niacin is a water-soluble B vitamin (B3) known to have favorable effects on multiple lipid parameters, including raising high-density lipoprotein cholesterol (HDL-C) levels and lowering triglycerides (TGs), lipoprotein(a), and low-density lipoprotein cholesterol (LDL-C). Although LDL-C remains the primary target of lipid-altering therapy, current guidelines emphasize HDL-C and other modifiable lipid factors as key secondary targets. Thus, niacin is considered an important therapeutic option to help reduce the risk of cardiovascular disease in patients with mixed dyslipidemia who, in addition to high LDL-C, have elevated TGs and low HDL-C. Although available prescription niacin products, including immediate-release niacin (IR; Niacor) and an extended-release niacin formulation (Niaspan), have demonstrated safety and efficacy in randomized clinical trials, confusion remains among health care providers and their patients regarding the various commercially available nonprescription dietary supplement niacin products. These dietary supplements, which include IR, sustained-release (SR), and "no-flush" or "flush-free" niacin products, are not subject to the same stringent US Food and Drug Administration regulations as prescription drugs. In fact, both the American Heart Association and the American Pharmacists Association recommend against the use of dietary supplement niacin as a substitute for prescription niacin. Although some dietary supplement IR and SR niacin products have demonstrated a lipid response in clinical trials, products labeled as "no-flush" or "flush-free" that are intended to avoid the common niacin-associated adverse effect of flushing generally contain minimal or no free, pharmacologically active niacin and therefore lack beneficial lipid-modifying effects. To clarify important differences between available prescription and dietary supplement niacin products, this article contrasts current regulatory standards for dietary supplements and prescription drugs and provides an overview of available clinical data from key trials of niacin.
Similar articles
- Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Guyton JR, et al. J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003. J Am Coll Cardiol. 2008. PMID: 18420099 Clinical Trial. - Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T. Van Ganse E, et al. Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003. Clin Ther. 2007. PMID: 17919548 - Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM. Fazio S, et al. Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13. Am J Cardiol. 2010. PMID: 20152243 Clinical Trial. - Understanding niacin formulations.
Pieper JA. Pieper JA. Am J Manag Care. 2002 Sep;8(12 Suppl):S308-14. Am J Manag Care. 2002. PMID: 12240702 Review. - A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH, Cheung BM, Tse HF. Yiu KH, et al. Expert Opin Investig Drugs. 2010 Mar;19(3):437-49. doi: 10.1517/13543781003623223. Expert Opin Investig Drugs. 2010. PMID: 20141348 Review.
Cited by
- B-Vitamin Levels in Human Milk among Different Lactation Stages and Areas in China.
Ren X, Yang Z, Shao B, Yin SA, Yang X. Ren X, et al. PLoS One. 2015 Jul 17;10(7):e0133285. doi: 10.1371/journal.pone.0133285. eCollection 2015. PLoS One. 2015. PMID: 26186707 Free PMC article. - Acute liver failure secondary to niacin toxicity.
Ellsworth MA, Anderson KR, Hall DJ, Freese DK, Lloyd RM. Ellsworth MA, et al. Case Rep Pediatr. 2014;2014:692530. doi: 10.1155/2014/692530. Epub 2014 Feb 12. Case Rep Pediatr. 2014. PMID: 24711953 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials